Effect of Patient Financial Incentives on Statin Adherence and Lipid Control: A Randomized Clinical Trial

Area of Science:

• Cardiovascular Disease Research
• Behavioral Economics in Health

Background:

• Financial incentives show potential for improving medication adherence and managing cardiovascular disease risk factors.
• Optimal incentive design for sustained adherence post-intervention remains unclear.

Purpose of the Study:

• To evaluate the impact of different 6-month financial incentive designs on statin adherence and low-density lipoprotein cholesterol (LDL-C) levels over 12 months.

Main Methods:

• A 4-group randomized clinical trial involving adults with cardiovascular disease risk and suboptimal LDL-C control.
• Interventions included daily medication reminders and electronic pill bottles, with financial incentives for adherence in three groups (sweepstakes, deadline sweepstakes, sweepstakes plus deposit contract).
• Primary outcome: change in LDL-C from baseline to 12 months; secondary: measured adherence at 6 months.

Main Results:

• All three financial incentive groups demonstrated significantly higher measured statin adherence at 6 months compared to the control group.
• Despite improved adherence, no significant differences in LDL-C level reductions were observed between the incentive groups and the control group at 12 months.
• Mean LDL-C reductions ranged from 32.4 to 36.5 mg/dL in incentive groups versus 33.6 mg/dL in the control group.

Conclusions:

• Financial incentives can effectively enhance medication adherence but do not necessarily translate to improved clinical outcomes like LDL-C reduction.
• Emphasizes the critical importance of measuring direct health outcomes rather than solely adherence in evaluating health behavior interventions.